Life Science Investing Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients 17 December
Life Science Investing Traws Pharma Reports Third Quarter 2025 Results and Business Highlights 13 November
Life Science Investing ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials 30 October
